Mason, John O <br/><br/>
Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients.  [electronic resource] 

 -  Retina (Philadelphia, Pa.)  Oct 2010 
 - 1386-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1539-2864 
<br/><br/><label>Standard No.: </label>10.1097/IAE.0b013e3181e09739  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Anticoagulants--administration & dosage<br/>Aspirin--administration & dosage<br/>Bevacizumab<br/>Choroidal Neovascularization--drug therapy<br/>Clopidogrel<br/>Eye Hemorrhage--epidemiology<br/>Female<br/>Humans<br/>Incidence<br/>Intravitreal Injections<br/>Macular Degeneration--drug therapy<br/>Male<br/>Middle Aged<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Ranibizumab<br/>Retrospective Studies<br/>Risk Factors<br/>Ticlopidine--administration & dosage<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Warfarin--administration & dosage